Keyword: VBI Vaccines

Here is some other vaccine news of note for the week.

Here is some other vaccine news of note for the week.

VBI-1501 showed neutralizing antibody activities against both fibroblast and epithelial cell infections.

After failing a phase 2 in solid-organ transplant patients, the CMV vaccine failed in hematopoietic cell transplant recipients too.

Here is some other vaccine news of note for the week.

The J.P. Morgan Healthcare Conference was a great place to suss out the general biopharma mood as 2018 begins.

Moderna unveiled two phase 1 prophylactic vaccine programs and a new Chikungunya antibody candidate at JPM.

VBI Vaccines is aiming for 2019 approval filings for its hepatitis B vaccine if a head-to-head trial against GSK's entrenched Engerix-B succeeds.

Dynavax is assuming the daunting task of challenging a Big Pharma with a small internal team.

Here's other vaccine news of note for this week.